Testicular Mesothelioma: An Analysis of Epidemiology, Patient Outcomes, and Prognostic Factors.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
04 2019
Historique:
received: 12 12 2018
revised: 10 01 2019
accepted: 12 01 2019
pubmed: 23 1 2019
medline: 14 6 2019
entrez: 23 1 2019
Statut: ppublish

Résumé

To characterize demographic features, clinical characteristics, and oncologic outcomes of mesothelioma of the testis. A population based search was performed using the National Cancer Institute's SEER 18 database. Patients diagnosed with malignant mesothelioma of the male genital organs from 1973 to 2015 were identified. Data on patient age, race, tumor laterality, histologic subtype, tumor extent, tumor size, tumor grade, treatment, cause of death, and survival months was collected. Primary outcomes were overall survival (OS) and disease-specific survival (DSS). A total of 113 patients with testicular mesothelioma were identified. The 5-year OS and DSS for all patients was 49% and 58%, and the 10-year OS and DSS was 33% and 45%, respectively. Biphasic mesotheliomas were associated with worse OS compared to general mesotheliomas and epithelioid subtypes (P = .043 and P = .039, respectively). Median survival time was not reached in patients with T1 disease while OS was 1.7 years and DSS was 1.8 years for patients with T4 disease (OS P = .002, DSS P <.001). Tumors greater than or equal to 4 cm were associated with worse OS and DSS (OS P = .025, DSS P = .047). This rare malignancy has significant mortality, with poor survival associated with biphasic subtypes, higher disease stage, and a critical tumor size cutoff of 4 cm.

Identifiants

pubmed: 30668959
pii: S0090-4295(19)30064-0
doi: 10.1016/j.urology.2019.01.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-144

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Azadeh Nazemi (A)

Institute of Urology, University of Southern California, Los Angeles, CA.

Nima Nassiri (N)

Institute of Urology, University of Southern California, Los Angeles, CA; USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Shane Pearce (S)

Institute of Urology, University of Southern California, Los Angeles, CA; USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Siamak Daneshmand (S)

Institute of Urology, University of Southern California, Los Angeles, CA; USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA. Electronic address: daneshma@med.usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH